Back to Peptides
PT-141 (Bremelanotide)
Hormone Regulation & Endocrine SupportPT-141 (Bremelanotide) is a melanocortin receptor agonist used for sexual enhancement. Unlike PDE5 inhibitors, it works in the brain to increase arousal and libido. It is FDA-approved for female sexual dysfunction and used off-label in men to improve sexual function without affecting vascular systems.
Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
0.75–1.75 mg Subcutaneous (SQ)
Use as needed ~45 minutes before sexual activity; max 1x per 24h
Standard Dose
1.75 mg
Cycle
4–8 weeks
then reassess
PT-141Bremelanotidesexual arousalmelanocortin agonistlibido
Dosing & Reconstitution Guide
The FDA-approved dose is 1.75 mg via subcutaneous injection before anticipated sexual activity. All other use cases are investigational or off-label.
Standard / Gradual Approach
10mg VialadvancedPhaseDoseVolume
Weeks 1–8500 mcg15 units (0.15 mL)
Weeks 9–121000 mcg30 units (0.30 mL)
Weeks 13–161500 mcg45 units (0.45 mL)
Protocol Summary
Subcutaneous (SQ): Use as needed ~45 minutes before sexual activity; max 1x per 24h · Dose range 0.75–1.75 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Use as needed, max once per day. Not intended for continuous daily use. Effects peak 45–90 min post-injection.
🧪 Quick Start
Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit
Starting Dose
500 mcg (15 units (0.15 mL))
Maintenance Dose
1500 mcg (45 units (0.45 mL))
Potential Benefits & Use Cases
PT-141 is approved only in its pharmaceutical form. Research versions are not approved for medical use or self-administration.
Significantly improves sexual desire, arousal, and reduces distress in premenopausal women with hypoactive sexual desire disorder (FDA-approved)
Improves erectile function in men — 34% vs 9% placebo reported significantly better function (human trial)
First erection typically ~30 minutes after administration (human trial)
Favorable cardiovascular safety across 43 clinical studies (3,500+ subjects) (human trial)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Activates melanocortin-4 receptor (MC4R) in the central nervous system
→Stimulates dopamine release and arousal pathways in hypothalamus
→Enhances libido by bypassing peripheral vascular signaling
→Independent of nitric oxide, making it viable for patients with cardiovascular risks
Lifestyle & Optimization
timing
Administer 45 minutes before sexual activity. Max 1 dose per 24 hours, 8 doses per month.
diet
Limit alcohol around dosing.
exercise
General health maintenance.
sleep
Adequate sleep and stress management. Open communication with partners. Address underlying contributors (stress, hormones).
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Transient BP elevation (~6/3 mmHg, peaks at 4 hours, returns baseline by 8–10 hours)
• Skin hyperpigmentation with repeated use
🧮 Dose Calculator
Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High with Tmax ~45–60 minutes
Oral Administration
Not viable; destroyed in digestive tract
Half-Life
2.5 hours
Degradation
Cleared via hepatic and renal metabolism
Tissue Specificity
CNS arousal centers: hypothalamus, brainstem
⚗️
Peptide Details
Molecular Weight
1025.2
Formula
C50H68N14O10
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
⚖️
Legal Status & Regulatory
RegionStatus
FDAApproved
EUNot Approved
AustraliaPrescription Only
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days; avoid freeze–thaw